The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Open accessAbstract
Angiogenesis has become an attractive target for drug therapy because of its key role in tumor growth. An extensive array of compounds is currently in preclinical development, with many now entering the clinic and/or achieving approval from the US Food and Drug Administration. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (eg, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and epidermal growth factor), receptor tyrosine kinases, and transcription factors such as hypoxia inducible factor, as well as molecules involved in mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling. Pharmacologic agents have been identified that target these pathways, yet for some agents (notably thalidomide), an understanding of the specific mechanisms of antitumor action has proved elusive. The following review describes key molecular mechanisms and novel therapies that are on the horizon for antiangiogenic tumor therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Role of Transforming Growth Factor β in Human Disease
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,427
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice
Lindahl, P., Johansson, B. R., Levéen, P., & Betsholtz, C. (1997) · Science · doi:10.1126/science.277.5323.242 · Cited by 2,226
(1999) · PubMed · Cited by 2,204
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF
Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., & Connolly, D. T. (1989) · Science · doi:10.1126/science.2479987 · Cited by 2,061
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis
Hellström, M., Phng, L.-K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., Nilsson, A.-K., Karlsson, L., Gaiano, N., et al. (2007) · Nature · doi:10.1038/nature05571 · Cited by 1,775
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
(2000) · PubMed · Cited by 1,445
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299
Vascular Endothelial Growth Factor
Ferrara, N. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179663 · Cited by 1,283
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Huang, L. E., Arany, Z., Livingston, D. M., & Bunn, H. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.32253 · Cited by 1,190
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy
Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,071
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Abraham, J. A., Mergia, A., Whang, J. L., Tumolo, A., Friedman, J., Hjerrild, K. A., Gospodarowicz, D., & Fiddes, J. C. (1986) · Science · doi:10.1126/science.2425435 · Cited by 1,015
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Weidemann, A., & Johnson, R. S. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.12 · Cited by 941
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 881
Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., & Semenza, G. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203781200 · Cited by 821
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Regulation of glut1 mRNA by Hypoxia-inducible Factor-1
Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., & Maity, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 771
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Fotsis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., & Schweigerer, L. (1994) · Nature · doi:10.1038/368237a0 · Cited by 736
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Lobov, I. B., Brooks, P. C., & Lang, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172161899 · Cited by 676
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 647
Sin, N., Meng, L., Wang, M. Q. W., Wen, J. J., Bornmann, W. G., & Crews, C. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6099 · Cited by 635
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
Maeda, K., Chung, Y.-S., Ogawa, Y., Kang, S.-M., Ogawa, M., Sawada, T., & Sowa, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a · Cited by 627
(2000) · PubMed · Cited by 614
(2001) · PubMed · Cited by 605
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Zagzag, D., Zhong, H., Scalzitti, J. M., Laughner, E., Simons, J. W., & Semenza, G. L. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2606::aid-cncr25>3.0.co;2-w · Cited by 604
Gale, N. W., Dominguez, M. G., Noguera, I., Pan, L., Hughes, V., Valenzuela, D. M., Murphy, A. J., Adams, N. C., Lin, H. C., Holash, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407290101 · Cited by 600
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C. M., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J., & van der Wall, E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.309 · Cited by 593
Adverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560
(2001) · PubMed · Cited by 557
Jiang, B., Agani, F. H., Passaniti, A., & Semenza, G. L. (1997) · PubMed · Cited by 532
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
Land, S. C., & Tee, A. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611782200 · Cited by 507
Suppression of tumor growth through disruption of hypoxia-inducible transcription
Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., & Livingston, D. M. (2000) · Nature Medicine · doi:10.1038/82146 · Cited by 501
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Sidky, Y. A., & Borden, E. C. (1987) · PubMed · Cited by 494
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K. C., & Harris, A. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2018 · Cited by 478
Liu, Y. V., Baek, J. H., Zhang, H., Diez, R., Cole, R. N., & Semenza, G. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.001 · Cited by 478
BIERIE, B., & MOSES, H. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.006 · Cited by 477
Interleukin-1β and Tumor Necrosis Factor- Stimulate DNA Binding of Hypoxia-Inducible Factor-1
Hellwig-Bürgel, T., Rutkowski, K., Metzen, E., Fandrey, J., & Jelkmann, W. (1999) · Blood · doi:10.1182/blood.v94.5.1561 · Cited by 475
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, S. J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.030 · Cited by 471
Properties and Biological Activities of Thioredoxins
Powis, G., & Montfort, W. R. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.261 · Cited by 451
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., & Fidler, I. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4562 · Cited by 440
The hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408
The role of the Angiopoietins in vascular morphogenesis
Thomas, M., & Augustin, H. G. (2009) · Angiogenesis · doi:10.1007/s10456-009-9147-3 · Cited by 405
Heparin Binds Endothelial Cell Growth Factor, the Principal Endothelial Cell Mitogen in Bovine Brain
Maciag, T., Mehlman, T., Friesel, R., & Schreiber, A. B. (1984) · Science · doi:10.1126/science.6382607 · Cited by 384
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Lenz, W., Pfeiffer, R. A., Kosenow, W., & Hayman, D. J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92665-x · Cited by 379
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
Zeng, Q., Li, S., Chepeha, D. B., Giordano, T. J., Li, J., Zhang, H., Polverini, P. J., Nor, J., Kitajewski, J., & Wang, C.-Y. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.004 · Cited by 360
The role of the EGFR signaling in tumor microenvironment
De Luca, A., Carotenuto, A., Rachiglio, A., Gallo, M., Maiello, M. R., Aldinucci, D., Pinto, A., & Normanno, N. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21260 · Cited by 359
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356
High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer
Pick, E., Kluger, Y., Giltnane, J. M., Moeder, C., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4511 · Cited by 356
The Role of Fibroblast Growth Factors in Tumor Growth
Korc, M., & Friesel, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789057006 · Cited by 355
Nistér, M., Libermann, T. A., Betsholtz, C., Pettersson, M., Claesson, L., Heldin, C., Schlessinger, J., & Westermark, B. (1988) · PubMed · Cited by 353
(2002) · PubMed · Cited by 349
Patel, N. S., Li, J.-L., Generali, D., Poulsom, R., Cranston, D. W., & Harris, A. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1208 · Cited by 349
Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., & Bukowski, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba4510 · Cited by 348
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
Satchi-Fainaro, R., Puder, M., Davies, J. W., Tran, H. T., Sampson, D. A., Greene, A. K., Corfas, G., & Folkman, J. (2004) · Nature Medicine · doi:10.1038/nm1002 · Cited by 345
Signalling hypoxia by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.111 · Cited by 341
Ishigami, S.-I., Arii, S., Furutani, M., Niwano, M., Harada, T., Mizumoto, M., Mori, A., Onodera, H., & Imamura, M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.688 · Cited by 338
Inhibition of Cell Motility by Interferon
Brouty-Boyé, D., & Zetter, B. R. (1980) · Science · doi:10.1126/science.6154315 · Cited by 326
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Burley, D. M., & Lenz, W. (1962) · The Lancet · doi:10.1016/s0140-6736(62)91217-5 · Cited by 324
TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype
Sainson, R. C. A., Johnston, D. A., Chu, H. C., Holderfield, M. T., Nakatsu, M. N., Crampton, S. P., Davis, J., Conn, E., & Hughes, C. C. W. (2008) · Blood · doi:10.1182/blood-2007-08-108597 · Cited by 321
Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent
Kusaka, M., Sudo, K., Fujita, T., Marui, S., Itoh, F., Ingber, D., & Folkman, J. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91529-l · Cited by 320
Liu, M., Bryant, M., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M. G., Ferrari, E., Nielsen, L. L., Prioli, N. A., et al. (1998) · PubMed · Cited by 309
(2000) · PubMed · Cited by 304
Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent
Bauer, K. S., Dixon, S. C., & Figg, W. D. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00046-x · Cited by 295
Self-citationThe Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2130 · Cited by 290
Mailhos, C., Modlich, U., Lewis, J., Harris, A., Bicknell, R., & Ish-Horowicz, D. (2001) · Differentiation · doi:10.1046/j.1432-0436.2001.690207.x · Cited by 288
Stiehl, D. P., Jelkmann, W., Wenger, R. H., & Hellwig-Bürgel, T. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02247-0 · Cited by 285
Targeting Hsp90: small-molecule inhibitors and their clinical development
Taldone, T., Gozman, A., Maharaj, R., & Chiosis, G. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.015 · Cited by 284
Platelet-Derived Growth Factor is Angiogenic In Vivo
Risau, W., Drexler, H., Mironov, V., Smits, A., Siegbahn, A., Funa, K., & Heldin, C.-H. (1992) · Growth Factors · doi:10.3109/08977199209046408 · Cited by 283
Kuenen, B. C., Rosen, L. S., Smit, E. F., Parson, M., Levi, M. M., Ruijter, R., Huisman, H., Kedde, M. A., Noordhuis, P., van der Vijgh, W. J. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1657 · Cited by 279
Lindner, V, Majack, R. A., & Reidy, M. A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114665 · Cited by 278
Koukourakis, M. I., Giatromanolaki, A. N., Skarlatos, J., Corti, L., Blandamura, S., Piazza, M., Gatter, K. C., & Harris, A. L. (2001) · PubMed · Cited by 271
(2001) · PubMed · Cited by 270
Pore, N., Jiang, Z., Gupta, A., Cerniglia, G., Kao, G. D., & Maity, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3090 · Cited by 268
Griffith, E. C., Su, Z., Niwayama, S., Ramsay, C. A., Chang, Y.-H., & Liu, J. O. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15183 · Cited by 262
Inoue, K., Ozeki, Y., Suganuma, T., Sugiura, Y., & Tanaka, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970115)79:2<206::aid-cncr2>3.0.co;2-i · Cited by 256
Anticancer strategies involving the vasculature
Heath, V. L., & Bicknell, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.52 · Cited by 255
The emerging role of TGF-β superfamily coreceptors in cancer
Bernabeu, C., Lopez-Novoa, J. M., & Quintanilla, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.003 · Cited by 254
Development and application of Hsp90 inhibitors
Solit, D. B., & Chiosis, G. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.007 · Cited by 251
(2003) · PubMed · Cited by 250
Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a
Kaban, L. B., Mulliken, J. B., Ezekowitz, R. A., Phil, D., Ebb, D., Smith, P. S., & Folkman, J. (1999) · Pediatrics · doi:10.1542/peds.103.6.1145 · Cited by 245
Tyrosine kinase inhibitors in cancer therapy
Madhusudan, S., & Ganesan, T. S. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.05.006 · Cited by 236
Olenyuk, B. Z., Zhang, G.-J., Klco, J. M., Nickols, N. G., Kaelin, W. G., & Dervan, P. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407617101 · Cited by 219
Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws
Kaban, L. B., Troulis, M. J., Ebb, D., August, M., Hornicek, F. J., & Dodson, T. B. (2002) · Journal of Oral and Maxillofacial Surgery · doi:10.1053/joms.2002.34975 · Cited by 219
R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
Cao, Y., Cao, R., & Hedlund, E.-M. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0337-z · Cited by 215
Angiogenic inhibitors: a new therapeutic strategy in oncology
Gasparini, G., Longo, R., Toi, M., & Ferrara, N. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0342 · Cited by 212
Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies
van Cruijsen, H., Giaccone, G., & Hoekman, K. (2005) · International Journal of Cancer · doi:10.1002/ijc.21479 · Cited by 203
Birner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rössler, K., Prodinger, A., Budka, H., & Hainfellner, J. A. (2001) · Cancer · doi:10.1002/1097-0142(20010701)92:1<165::aid-cncr1305>3.0.co;2-f · Cited by 195
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Zangari, M., Fink, L. M., Elice, F., Zhan, F., Adcock, D. M., & Tricot, G. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3875 · Cited by 194
Microvascular Injury in Pathogenesis of Interferon-Induced Necrosis of Subcutaneous Tumors in Mice
Dvorak, H. F., & Gresser, I. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.497 · Cited by 192
Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis
Shim, W. S. N., Ho, I. A. W., & Wong, P. E. H. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0072 · Cited by 187
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis
Thurston, G., & Kitajewski, J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604484 · Cited by 182
Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 WAF1/CIP1
Zhang, Y., Griffith, E. C., Sage, J., Jacks, T., & Liu, J. O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6427 · Cited by 175
Hainaud, P., Contrerès, J.-O., Villemain, A., Liu, L.-X., Plouët, J., Tobelem, G., & Dupuy, E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4226 · Cited by 175
An orally delivered small-molecule formulation with antiangiogenic and anticancer activity
Benny, O., Fainaru, O., Adini, A., Cassiola, F., Bazinet, L., Adini, I., Pravda, E., Nahmias, Y., Koirala, S., Corfas, G., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1415 · Cited by 171
Anti-angiogenic therapy: Rationale, challenges and clinical studies
Longo, R., Sarmiento, R., Fanelli, M., Capaccetti, B., Gattuso, D., & Gasparini, G. (2002) · Angiogenesis · doi:10.1023/a:1024532022166 · Cited by 170
Hypoxia-inducible factor (HIF) in human tumorigenesis.
Mabjeesh, N. J., & Amir, S. (2007) · PubMed · doi:10.14670/hh-22.559 · Cited by 165
Cook, K. M., Hilton, S. T., Mecinović, J., Motherwell, W. B., Figg, W. D., & Schofield, C. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.009498 · Cited by 161
Self-citationMack, F. A., Rathmell, W. K., Arsham, A. M., Gnarra, J., Keith, B., & Simon, M. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00240-4 · Cited by 160
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 159
A Notch1 Ectodomain Construct Inhibits Endothelial Notch Signaling, Tumor Growth, and Angiogenesis
Funahashi, Y., Hernandez, S. L., Das, I., Ahn, A., Huang, J., Vorontchikhina, M., Sharma, A., Kanamaru, E., Borisenko, V., DeSilva, D. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6499 · Cited by 151
TNP-470: an angiogenesis inhibitor in clinical development for cancer
Kruger, E. A., & Figg, W. D. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1383 · Cited by 150
Self-citationSteeghs, N., Nortier, J. W. R., & Gelderblom, H. A. J. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9227-1 · Cited by 148
Logothetis, C. J., Wu, K. K., Finn, L. D., Daliani, D., Figg, W. D., Ghaddar, H. M., & Gutterman, J. U. (2001) · PubMed · Cited by 140
Self-citationA Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
Bhargava, P., Marshall, J. L., Rizvi, N. A., Dahut, W., Yoe, J., Figuera, M., Phipps, K., Ong, V. S., Kato, A., & Hawkins, M. (1999) · PubMed · Cited by 136
Modulating Hypoxia-Inducible Transcription by Disrupting the HIF-1–DNA Interface
Nickols, N. G., Jacobs, C. S., Farkas, M. E., & Dervan, P. B. (2007) · ACS Chemical Biology · doi:10.1021/cb700110z · Cited by 128
Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470
Kudelka, A. P., Verschraegen, C. F., & Loyer, E. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804023381412 · Cited by 126
Gan, H. K., Šeruga, B., & Knox, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902980171 · Cited by 121
Berger, W., Setinek, U., Mohr, T. T., Kindås-Mügge, I., Vetterlein, M., Dekan, G., Eckersberger, F., Caldas, C. H., & Micksche, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991029)83:3<415::aid-ijc19>3.0.co;2-y · Cited by 115
Tew, W. P., Colombo, N., Ray-Coquard, I. L., Oza, A. M., del Campo, J., Scambia, G., & Spriggs, D. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5508 · Cited by 106
Current status of angiogenesis inhibitors combined with radiation therapy
Nieder, C., Wiedenmann, N. E., Andratschke, N. H., & Molls, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.03.006 · Cited by 104
Ramanathan, R. K., Kirkpatrick, D. L., Belani, C. P., Friedland, D., Green, S. B., Chow, H. ‐. S., Cordova, C. A., Stratton, S. P., Sharlow, E. R., Baker, A. F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2250 · Cited by 104
Sutherland, T. E., Anderson, R. L., Hughes, R. A., Altmann, E., Schuliga, M. J., Ziogas, J., & Stewart, A. G. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.05.005 · Cited by 85
Marler, J. J., Rubin, J. B., Trede, N. S., Connors, S. L., Grier, H. E., Upton, J. M., Mulliken, J. B., & Folkman, J. (2002) · PEDIATRICS · doi:10.1542/peds.109.2.e37 · Cited by 78
Drug resistance associated with antiangiogenesis therapy
Eikesdal, H. P., & Kalluri, R. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.006 · Cited by 70
Delmas, C., End, D. W., Rochaix, P., Favre, G., Toulas, C., & Moyal, E. C. (2003) · PubMed · Cited by 70
Tipifarnib: farnesyl transferase inhibition at a crossroads
Mesa, R. A. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.3.313 · Cited by 64
Kvasnicka, H. M., Thiele, J., Staib, P., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2734 · Cited by 61
Biological mechanisms of bevacizumab-associated adverse events
Higa, G. M., & Abraham, J. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.68 · Cited by 61
A developmental model for thalidomide defects
Tabin, C. J. (1998) · Nature · doi:10.1038/24516 · Cited by 51
Clinical biomarkers of angiogenesis inhibition
Brown, A. P., Citrin, D. E., & Camphausen, K. A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9143-x · Cited by 50
Gradishar, W. J., Vogelzang, N. J., Kilton, L. J., Leibach, S. J., Rademaker, A. W., French, S., & Benson, A. B. (1995) · Investigational New Drugs · doi:10.1007/bf00872868 · Cited by 49
Gazzaniga, P., Gandini, O., Gradilone, A., Silvestri, I., Giuliani, L., Magnanti, M., Gallucci, M., Saccani, G., Frati, L., & Aglianò, A. M. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.6.1123 · Cited by 49
Wang, W., Jia, W., Xu, G., Wang, Z.-H., Li, J., Ma, J., Ge, Y., Xie, S., & Yu, J.-H. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0605-3 · Cited by 38
Kim, R., Emi, M., Arihiro, K., Tanabe, K., Uchida, Y., & Toge, T. (2005) · Cancer · doi:10.1002/cncr.20973 · Cited by 35
Antiangiogenic Drugs: Current Knowledge and New Approaches to Cancer Therapy
Mauriz, J. L., & González‐Gallego, J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21286 · Cited by 34
Fang, J. S., Cao, Z., Chen, Y., Reed, E., & Jiang, B. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.178 · Cited by 28
Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer
Nahari, D., Satchi‐Fainaro, R., Chen, M., Mitchell, I. C., Task, L., Liu, Z., Kihneman, J., Carroll, A. B., Terada, L. S., & Nwariaku, F. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0554 · Cited by 27
Current status and future prospects for anti-angiogenic therapies in cancer
Staton, C. A., Brown, N. J., & Reed, M. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903196737 · Cited by 25
The epidermal growth factor system of ligands and receptors in cancer
Gullick, W. J. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70035-8 · Cited by 18
Cited by
Szabo, C., Coletta, C., Chao, C., Módis, K., Szczesny, B., Papapetropoulos, A., & Hellmich, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306241110 · Cited by 763
The Role of Angiogenesis in Cancer Treatment
Rajabi, M., & Mousa, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020034 · Cited by 656
Boldrini, M., Hen, R., Underwood, M. D., Rosoklija, G. B., Dwork, A. J., Mann, J. J., & Arango, V. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.024 · Cited by 348
Mross, K., Frost, A., Steinbild, S., Hedbom, S., Büchert, M., Fasol, U., Unger, C., Krätzschmar, J., Heinig, R., Boix, O., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1900 · Cited by 335
Peptide-based cancer therapy: Opportunity and challenge
Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., & Li, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.002 · Cited by 306
Metadata
- Authors
- Cook, K. M., & Figg, W. D.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2010-06-16
- Volume
- 60
- Issue
- 4
- Pages
- 222-243
- ISSN
- 0007-9235 (ISSN-L)
- OpenAlex
- W2055437192
- Cited by
- 474
- References
- 189
- FWCI
- 16.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.